UOC
GLUE icon

UBS O'Connor’s Monte Rosa Therapeutics GLUE Stock Holding History

UBS O'Connor’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-44,247
Closed -$250K – 554
2023
Q4 		$250K Sell
44,247
-41,231
-48% -$162K 0.01% 394
2023
Q3 		$409K Sell
85,478
-15,000
-15% -$96.6K 0.01% 416
2023
Q2 		$688K Buy
100,478
+4,950
+5% +$32K 0.01% 416
2023
Q1 		$744K Buy
+95,528
New +$664K 0.02% 433
2022
Q4 		– Sell
-91,615
Closed -$748K – 133
2022
Q3 		$748K Sell
91,615
-10,032
-10% -$92.1K 0.01% 774
2022
Q2 		$983K Buy
+101,647
New +$1.02M 0.01% 769

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS O'Connor's GLUE Position: Q1 2024 in Review

UBS O'Connor sold out of Monte Rosa Therapeutics (GLUE) in Q1 2024, closing a stake of 44,247 shares — an estimated $250K sold.

UBS O'Connor first reported a position in GLUE in Q2 2022 and held it in 6 quarters. The position peaked at $983K in Q2 2022. 68 funds tracked by Wall St. Rank hold GLUE as of Q1 2024.

  • UBS O'Connor reported no remaining Monte Rosa Therapeutics position as of Q1 2024 after selling out during the quarter.
  • UBS O'Connor sold 44,247 Monte Rosa Therapeutics shares in Q1 2024, an estimated $250K.
  • UBS O'Connor first reported a position in Monte Rosa Therapeutics in Q2 2022 and held it in 6 quarters.
  • UBS O'Connor's Monte Rosa Therapeutics position peaked at $983K in Q2 2022.
  • 68 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2024.

Based on UBS O'Connor's 13F filing for Q1 2024, filed 15 May 2024.